Experimental Cancer Drug Removes Tumours In All Patients In Small Scale Trial

Tumours in all 12 patients with rectal cancer vanished at the end of the trial, the study says.

In an unprecedented first of its kind, every single person in a 12-person group of people with cancer had their tumours vanish fully after being administered an experimental cancer treatment drug treatment called Dostarlimab.

The US Food and Drug Administration (FDA) had given the experimental drug Dostarlimab-gxly, a drug candidate created by GlaxoSmithKline, approval for use in patients with recurrent tumours, in August 2021.

The trial was performed at the Memorial Sloan Kettering Cancer Center in New York.

The study, published in the New England Journal of Medicine states:

"Single dose dostarlimab was administered every three weeks for six months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery."